SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...

Last week, the FDA approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. This approval will help offer additional aid for the many individuals throughout the world who live ...

ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced results of a Phase III trial demonstrating that its antiepileptic drug (AED) in development Keppra XR(TM) (levetiracetam) extended-release tablets ...

ATLANTA An investigational drug can reduce seizures in adolescents and adults with epilepsy when added on to existing treatments, according to results of a late-stage clinical trial. The 405-patient ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved XCOPRI for adults with partial-onset seizures, its manufacturer announced. “The ...

BRUSSELS, BELGIUM--(MARKET WIRE)--Oct 29, 2008 -- Brussels, BELGIUM, October 29, 2008 at 7:00 CET- press release, regulated information - UCB announced today that the U.S. Food and Drug Administration ...

child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiepileptic lacosamide UCB (UCB Pharma SA) for partial-onset ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...